EP
APTO

Eversept Partners’s Aptose Biosciences, Inc. APTO Stock Holding History

Eversept Partners’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-178
Closed -$478K – 110
2021
Q1 		$478K Buy
+178
New +$353K 0.04% 83

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Eversept Partners's APTO Position: Q2 2021 in Review

Eversept Partners sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 178 shares — an estimated $478K sold.

Eversept Partners first reported a position in APTO in Q1 2021 and held it in 1 quarter. The position peaked at $478K in Q1 2021. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Eversept Partners reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Eversept Partners sold 178 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $478K.
  • Eversept Partners first reported a position in Aptose Biosciences, Inc. in Q1 2021 and held it in 1 quarter.
  • Eversept Partners's Aptose Biosciences, Inc. position peaked at $478K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.